Rein Therapeutics宣布,其研发的药物Lti-03已获得美国食品药品监督管理局(FDA)授予的快速通道资格,用于治疗特发性肺纤维化。这一里程碑式的进展,标志着该药物在应对这一棘手疾病方面迈出了关键一步。快速通道资格的获得,旨在加速针对严重疾病且未满足医疗需求的新药研发与审评进程,为患者带来更早获得创新疗法的希望。
Rein Therapeutics宣布,其研发的药物Lti-03已获得美国食品药品监督管理局(FDA)授予的快速通道资格,用于治疗特发性肺纤维化。这一里程碑式的进展,标志着该药物在应对这一棘手疾病方面迈出了关键一步。快速通道资格的获得,旨在加速针对严重疾病且未满足医疗需求的新药研发与审评进程,为患者带来更早获得创新疗法的希望。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.